FrancophonIA/ELRC3.0 huggingface dataset:
English: Study 032 was a 12-month, randomized, double-blind, parallel-group efficacy study in 25 patients aged 2 years and older who were naïve to ERT (defined as having not been treated with ERT for at least 30 months prior to study entry).
Slovenian: Študija 032 je bila 12-mesečna randomizirana, dvojno slepa študija učinkovitosti z vzporednimi skupinami pri 25 bolnikih, starih več kot 2 leti, ki predhodno niso prejemali NEZ (opredeljeno kot to, da niso prejemali NEZ vsaj 30 mesecev pred vstopom v študijo).
English: Study 025 was a 9 month, open-label study in 12 adult (≥18 years) patients who were naïve to ERT (defined as having not been treated with ERT for at least 12 months prior to study entry).
Slovenian: Študije zdravljenja predhodno nezdravljenih bolnikov Študija 025 je bila 9-mesečna odprta študija pri 12 odraslih bolnikih (starih ≥ 18 let), ki predhodno niso prejemali NEZ (opredeljeno kot to, da niso prejemali NEZ vsaj 12 mesecev pred vstopom v študijo).
English: In this one event, the antibodies were determined to be neutralising in an in vitro assay.
Slovenian: V tem primeru so ugotovili, da protitelesa nevtralizirajo zdravilo v preizkusih in vitro.
English: Description of selected adverse reactions Vomiting
Slovenian: Opis izbranih neželenih učinkov
English: VPRIV is a long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.
Slovenian: Zdravilo VPRIV je namenjeno dolgoročnemu nadomestnemu encimskemu zdravljenju (NEZ) bolnikov z Gaucherjevo boleznijo tipa 1.
English: Ask your doctor or pharmacist for advice before this medicine is used.
Slovenian: Pred uporabo tega zdravila se posvetujte z zdravnikom ali farmacevtom.
English: What VPRIV is and what it is used for What you need to know before VPRIV is used How VPRIV is used
Slovenian: Kaj je zdravilo VPRIV in za kaj ga uporabljamo Kaj morate vedeti preden boste uporabili zdravilo VPRIV Kako uporabljati zdravilo VPRIV Možni neželeni učinki
English: OUTER CARTON - 400 UNITS (25 vial pack)
Slovenian: ZUNANJA ŠKATLA - 400 ENOT (pakiranje s 25 vialami)
English: Powder for solution for infusion 5 vials
Slovenian: Prašek za raztopino za infundiranje 5 vial
English: VPRIV is a powder for solution for infusion.
Slovenian: Zdravilo VPRIV je prašek za raztopino za infundiranje.
English: Meaningful increases from baseline were observed in the 45 Units/kg dose group in haemoglobin concentration (+2.4 g/dl) and platelet count (+40.9 x 10
Slovenian: V skupini, ki je prejemala odmerek 45 enot/kg, so opazili klinično pomembno povečanje koncentracije hemoglobina (+ 2,4 g/dl) in števila trombocitov (+ 40,9 x 10
English: Powder for solution for infusion 1 vial
Slovenian: Prašek za raztopino za infundiranje 1 viala
English: OUTER CARTON - 400 UNITS (5 vial pack)
Slovenian: ZUNANJA ŠKATLA - 400 ENOT (pakiranje s 5 vialami)
English: In the clinical trials, one of 94 (1%) patients developed IgG-class antibodies to velaglucerase alfa.
Slovenian: V kliničnih preskušanjih so se protitelesa razreda IgG proti velaglucerazi alfa pojavila pri enem od 94 bolnikov (1 %).
English: There were no statistically significant differences between velaglucerase alfa and imiglucerase in changes in platelet counts and liver and spleen volumes after 9 months of velaglucerase alfa treatment, and in the time to first haemoglobin response (defined as 1 g/dl increase from baseline).
Slovenian: Pri številu trombocitov in prostornini jeter in vranice po 9 mesecih zdravljenja z velaglucerazo alfa ter v času do prvega odziva hemoglobina (opredeljeno kot povišanje koncentracije za 1 g/dl glede na izhodiščno vrednost) ni bilo statistično pomembnih razlik med velaglucerazo alfa in imiglucerazo.
English: Appropriate medical support, including adequately trained personnel in emergency measures, should be readily available when velaglucerase alfa is administered.
Slovenian: Pri dajanju velagluceraze alfa mora biti takoj na voljo ustrezna medicinska podpora, vključno z osebjem, ki je ustrezno usposobljeno za izvajanje nujnih ukrepov.
English: OUTER CARTON - 400 UNITS (single vial pack)
Slovenian: ZUNANJA ŠKATLA - 400 ENOT (pakiranje z eno vialo)
English: VPRIV contains sodium
Slovenian: Zdravilo VPRIV vsebuje natrij
English: Sodium citrate dihydrate
Slovenian: saharoza natrijev citrat, dihidrat monohidrat citronske kisline polisorbat 20
English: Velaglucerase alfa serum concentrations rose rapidly for the first 20 minutes of the 60-minute infusion before leveling off, and Cmax was typically attained between 40 and 60 minutes after the start of the infusion.
Slovenian: Koncentracije velagluceraze alfa v serumu so se v prvih 20 minutah 60-minutnega infundiranja hitro zvišale, nato pa so se ustalile.
English: If anaphylactic or other acute reactions occur, immediately discontinue the infusion and initiate appropriate medical treatment.
Slovenian: Če se pojavijo anafilaktična ali druge akutne reakcije, nemudoma prekinite infuzijo in začnite z ustreznim medicinskim zdravljenjem (glejte poglavje 4.4).
English: The most frequently reported symptoms of hypersensitivity include nausea, rash, dyspnoea, back pain, chest discomfort (including chest tightness), urticaria, arthralgia, and headache.
Slovenian: Simptomi preobčutljivosti, o katerih najpogosteje poročajo, vključujejo navzeo, izpuščaj, dispnejo, bolečino v hrbtu, neugodje v prsih (vključno s stiskanjem v prsih), urtikarijo, artralgijo in glavobol.
English: Extractable volume
Slovenian: Volumen, ki ga lahko odvzamete
English: Overall velaglucerase alfa group (N=39)
Slovenian: Celotna skupina z velaglucerazo alfa
English: The total volume required is diluted in 100 ml of sodium chloride 9 mg/ml (0.9%) solution for infusion.
Slovenian: Razredčite zahtevan volumen v 100 ml 0,9-odstotne raztopine natrijevega klorida za infundiranje.
English: Posology The recommended dose is 60 Units/kg administered every other week.
Slovenian: Odmerjanje Priporočeni odmerek je 60 enot/kg, vsak drugi teden.
English: White to off-white powder.
Slovenian: Bel ali belkast prašek.
English: A risk-benefit assessment is required for women with Gaucher disease who are considering pregnancy.
Slovenian: Pri ženskah z Gaucherjevo boleznijo, ki si želijo zanositi, je treba oceniti tveganja in koristi zdravljenja.
English: It is not known whether velaglucerase alfa is excreted in human milk.
Slovenian: Podatkov iz študij pri doječih ženskah ni. Ni znano, ali se velagluceraza alfa izloča v materino mleko.
English: Table 1: Adverse reactions reported with VPRIV observed in patients with type 1 Gaucher disease Italic text denotes post-marketing event.
Slovenian: Preglednica 1: Neželeni učinki, o katerih so poročali pri uporabi zdravila VPRIV, ki so jih opazili pri bolnikih z Gaucherjevo boleznijo tipa 1.
English: Infusion-related reaction, asthenia/fatigue, pyrexia/body temperature increased
Slovenian: Splošne težave in spremembe na mestu aplikacije reakcije, povezane z infundiranjem, astenija/utrujenost, pireksija/zvišana telesna temperatura neugodje v prsih
English: No dosing adjustment is recommended in patients with renal or hepatic impairment based on current knowledge of the pharmacokinetics and pharmacodynamics of velaglucerase alfa.
Slovenian: Na podlagi trenutnega znanja o farmakokinetiki in farmakodinamiki velagluceraze alfa prilagoditev odmerka pri bolnikih z okvaro ledvic in jeter ni priporočljiva.
English: Improvement from baseline in mean lumbar spine and femoral neck bone mineral density (BMD) Z-scores were observed at month 24 (0.4; 95% CI 0.1, 0.7) and month 33 (0.4; 95% CI 0.2, 0.6), respectively.
Slovenian: (0,4; 95-odstotni IZ 0,1, 0,7) oziroma 33. mesecu (0,4; 95-odstotni IZ 0,2, 0,6).
English: In this study, haemoglobin concentration, platelet count, liver volume and spleen volume were assessed in treatment-naïve patients after 24 months of treatment.
Slovenian: V tej študiji so pri bolnikih, ki se prej še niso zdravili, po 24 mesecih zdravljenja ocenili koncentracije hemoglobina, število trombocitov, prostornino jeter in prostornino vranice.
English: - Apart from symptoms of hypersensitivity reactions infusion-related reactions might show as dizziness, high blood pressure, tiredness, fever, itching, or blurry vision.
Slovenian: - Poleg simptomov preobčutljivostnih reakcij se lahko reakcije, povezane z infundiranjem, pokažejo kot omotica, visok krvni tlak, utrujenost, zvišana telesna temperatura, srbenje ali zamegljen vid. - Če se pojavijo kateri koli od teh simptomov, morate takoj obvestiti zdravnika.
English: The mean absolute increase from baseline in haemoglobin concentrations was 1.624 g/dl (±0.223 SE) following 9 months of treatment with velaglucerase alfa.
Slovenian: Po 9 mesecih zdravljenja z velaglucerazo alfa je bilo povprečno absolutno zvišanje koncentracije hemoglobina glede na izhodiščno vrednost 1,624 g/dl (± 0,223 SD).
English: This increase in haemoglobin concentration was demonstrated to be clinically and statistically non-inferior to imiglucerase (mean treatment difference of change from baseline to 9 months [velaglucerase alfa - imiglucerase]: 0.135 g/dl).
Slovenian: (povprečna razlika spremembe pri zdravljenju od izhodiščne vrednosti do 9 mesecev [velagluceraza alfa - imigluceraza]: 0,135 g/dl).
English: Hypersensitivity reactions, including symptoms consistent with anaphylaxis, have been reported in patients in clinical studies and in post-marketing experience.
Slovenian: V kliničnih študijah in izkušnjah po prihodu zdravila na trg so pri bolnikih poročali o preobčutljivostnih reakcijah, vključno s simptomi, ki se skladajo z anafilaksijo.
English: What VPRIV contains
Slovenian: Kaj vsebuje zdravilo VPRIV
English: Symptoms consistent with anaphylaxis have been reported in patients in clinical studies and in post-marketing experience.
Slovenian: V kliničnih študijah in izkušnjah po prihodu zdravila na trg so poročali o simptomih, ki ustrezajo anafilaksiji.
English: Sucrose
Slovenian: Odmerek
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Slovenian: DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 26. avgust 2010
English: VPRIV must not be used:
Slovenian: Ne uporabljajte zdravila VPRIV:
English: Contains sodium, see leaflet for further information.
Slovenian: Shranjevanje zdravila VPRIV Vsebina pakiranja in dodatne informacije
English: The marketing authorisation holder is Boehringer Ingelheim International GmbH.
Slovenian: Imetnik dovoljenja za promet z zdravilom je družba Boehringer Ingelheim International GmbH.
English: The results of the second study were insufficient to prove the long-term effectiveness of Mirapexin.
Slovenian: Rezultati druge študije niso bili zadostni, da bi dokazali dolgoročno učinkovitost zdravila Mirapexin.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Mirapexin on 23 February 1998.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Mirapexin, veljavno po vsej Evropski uniji, odobrila dne 23. februarja 1998.
English: The full EPAR for Mirapexin can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Mirapexin je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: This document is a summary of the European Public Assessment Report (EPAR) for Mirapexin.
Slovenian: Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Mirapexin.
English: Mirapexin tablets should be swallowed with water.
Slovenian: Tablete Mirapexin je treba pogoltniti z vodo.
English: For more information about treatment with Mirapexin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Mirapexin preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
English: Mirapexin is used when a specific cause for the disorder cannot be identified.
Slovenian: Zdravilo Mirapexin se uporablja takrat, kadar točnega vzroka motnje ni mogoče ugotoviti.
English: Mirapexin must be given less often in patients who have problems with their kidneys.
Slovenian: Zdravilo Mirapexin je treba dajati manj pogosto pri bolnikih, ki imajo težave z ledvicami.
English: Mirapexin is used to treat the symptoms of the following diseases:
Slovenian: Zdravilo Mirapexin se uporablja za zdravljenje simptomov naslednjih bolezni:
English: Other information about Mirapexin:
Slovenian: Druge informacije o zdravilu Mirapexin:
English: Mirapexin pramipexole
Slovenian: Mirapexin pramipeksol
English: Mirapexin can be used either on its own or in combination with levodopa (another medicine for Parkinson's disease), at any stage of disease including the later stages when levodopa starts becoming less effective;
Slovenian: Zdravilo Mirapexin se lahko uporablja bodisi samostojno ali v kombinaciji z levodopo (drugim zdravilom za zdravljenje Parkinsonove bolezni) v katerem koli stadiju bolezni, vključno s poznimi stadiji, ko začne učinek levodope popuščati;
English: Four studies compared Mirapexin with placebo (a dummy treatment): one study in 360 patients with advanced disease who were already taking levodopa that was starting to become less effective, and three studies in a total of 886 patients with early disease who were not receiving levodopa.
Slovenian: V štirih študijah so zdravilo Mirapexin primerjali s placebom (zdravilom brez zdravilne učinkovine): v eni študiji s 360 bolniki z napredovalo boleznijo, ki so že jemali levodopo, katere učinkovitost je začela upadati, in v treh študijah s skupno 886 bolniki z boleznijo v zgodnjem stadiju, ki niso prejemali levodope.
English: For restless legs syndrome, Mirapexin immediate-release tablets should be taken once a day, two to three hours before going to bed.
Slovenian: Pri sindromu nemirnih nog je treba tablete zdravila Mirapexin s takojšnjim sproščanjem vzeti enkrat na dan, dve do tri ure pred spanjem.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Mirapexin.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Mirapexin, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Mirapexin should not be used in people who may be hypersensitive (allergic) to pramipexole or any of the other ingredients.
Slovenian: Zdravila Mirapexin ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) pramipeksol ali katero koli drugo sestavino zdravila.
English: Mirapexin was also more effective than levodopa at improving movement symptoms in early disease.
Slovenian: Zdravilo Mirapexin je bilo tudi učinkovitejše od levodope pri izboljšanju motoričnih simptomov pri bolezni v zgodnjem stadiju.
English: The CHMP decided that Mirapexin's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Mirapexin večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
English: The active substance in Mirapexin, pramipexole, is a dopamine agonist (a substance that imitates the action of dopamine).
Slovenian: Zdravilna učinkovina zdravila Mirapexin, pramipeksol, je dopaminski agonist (snov, ki posnema delovanje dopamina).
English: The fifth study compared Mirapexin with levodopa in 300 patients with early disease, and measured the number of patients who had movement symptoms.
Slovenian: V peti študiji so primerjali zdravilo Mirapexin z levodopo pri 300 bolnikih z boleznijo v zgodnjem stadiju in ugotavljali število bolnikov z motoričnimi simptomi.
English: Mirapexin is a medicine that contains the active substance pramipexole.
Slovenian: Mirapexin je zdravilo, ki vsebuje zdravilno učinkovino pramipeksol.
English: In the study of patients with advanced Parkinson's disease, patients taking Mirapexin immediaterelease tablets had larger improvements after 24 weeks of steady-dose treatment than those taking placebo.
Slovenian: V študiji z bolniki z napredovalo Parkinsonovo boleznijo je bilo pri bolnikih, ki so jemali tablete Mirapexin s podaljšanim sproščanjem, po 24 tednih zdravljenja s stalnim odmerkom doseženo večje izboljšanje kot pri bolnikih, ki so jemali placebo.
English: In restless legs syndrome, Mirapexin immediate-release tablets were more effective than placebo at reducing symptoms over 12 weeks, but the difference between placebo and Mirapexin was greatest after four weeks before getting smaller.
Slovenian: Pri sindromu nemirnih nog so bile tablete Mirapexin s takojšnjim sproščanjem pri zmanjševanju simptomov po 12 tednih učinkovitejše od placeba, razlika med zdravilom Mirapexin in placebom pa je bila največja po štirih tednih, nato se je začela zmanjševati.
English: What benefit has Mirapexin shown during the studies?
Slovenian: Kakšne koristi je zdravilo Mirapexin izkazalo med študijami?
English: The most common side effect with Mirapexin (seen in more than 1 patient in 10) is nausea (feeling sick).
Slovenian: Najpogostejši neželeni učinek zdravila Mirapexin (opažen pri 1 bolniku izmed 10) je navzeja (slabost).
English: The second included 150 patients who took Mirapexin for six months, and compared the effects of remaining on Mirapexin with switching to placebo.
Slovenian: V drugo študijo je bilo vključenih 150 bolnikov, ki so zdravilo Mirapexin jemali šest mesecev, v njej pa so učinke nadaljevanja jemanja zdravila Mirapexin primerjali z učinki prehoda na placebo.
English: In Parkinson's disease, Mirapexin immediate-release tablets have been studied in five main studies.
Slovenian: Pri Parkinsonovi bolezni so tablete Mirapexin s takojšnjim sproščanjem proučevali v petih glavnih študijah.
English: What is the risk associated with Mirapexin?
Slovenian: Kakšna tveganja so povezana z zdravilom Mirapexin?
English: For the full list of all side effects reported with Mirapexin, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Mirapexin, glejte navodilo za uporabo.
English: In restless legs syndrome, Mirapexin immediate-release tablets have been studied in two main studies.
Slovenian: Pri sindromu nemirnih nog so tablete zdravila Mirapexin s takojšnjim sproščanjem proučevali tudi v dveh glavnih študijah.
English: Why has Mirapexin been approved?
Slovenian: Zakaj je bilo zdravilo Mirapexin odobreno?
English: The first compared Mirapexin with placebo over 12 weeks in 344 patients and measured the improvement in symptoms.
Slovenian: V prvi so več kot 12 tednov primerjali zdravilo Mirapexin s placebom pri 344
English: How does Mirapexin work?
Slovenian: Kako zdravilo Mirapexin deluje?
English: What is Mirapexin used for?
Slovenian: Za kaj se zdravilo Mirapexin uporablja?
English: How has Mirapexin been studied?
Slovenian: Kako je bilo zdravilo Mirapexin raziskano?
English: What is Mirapexin?
Slovenian: Kaj je zdravilo Mirapexin?
English: How is Mirapexin used?
Slovenian: Kako se zdravilo Mirapexin uporablja?
English: The MAH should submit a revised risk management plan including proposals for evaluating the effectiveness of the risk minimisation measures.
Slovenian: Imetnik dovoljenja za promet z zdravilom mora predložiti posodobljen načrt obvladovanja tveganja, vključno s predlogi za vrednotenje učinkovitosti ukrepov za zmanjševanje tveganja.
English: Conditions to the marketing authorisations for Numeta G16%E and associated names
Slovenian: Pogoji dovoljenj za promet z zdravilom Numeta G16%E in povezanimi imeni
English: The MAH should conduct a prospective non-interventional postauthorisation safety study to further evaluate magnesium levels observed in term newborn infants and children up to two years of age treated with Numeta G16%E in routine clinical practice.
Slovenian: Imetnik dovoljenja za promet z zdravilom mora opraviti prospektivno, neintervencijsko študijo varnosti po pridobitvi dovoljenja za promet z zdravilom, s katero bo nadalje ocenil ravni magnezija, opažene pri donošenčkih in otrocih, starih do dveh let, ki se zdravijo z zdravilom Numeta G16%E v rutinski klinični praksi.
English: National competent authorities of Member States or reference Member State if applicable, shall ensure that the following conditions are fulfilled by the MAH for Numeta G16%E:
Slovenian: Pristojne nacionalne agencije držav članic ali referenčne države članice, če je primerno, zagotovijo, da imetnik(i) dovoljenja za promet z zdravilom Numeta G16%E izpolnjuje(jo) naslednje pogoje:
English: By the end of Q3 2015 Within 3 months after CMDh agreement
Slovenian: Do konca 3. četrtine leta
English: Within 3 months after CMDh agreement
Slovenian: Priloga V Pogoji dovoljenj za promet z zdravili
English: This will help to protect against the disease.
Slovenian: To bo pripomoglo k zaščiti pred boleznijo.
English: In very rare cases a higher temperature may occur for up to 2 days.
Slovenian: V zelo redkih primerih se lahko pojavi povišana telesna temperatura, ki traja do 2 dni.
English: As with any vaccine rare, occasional allergic reactions may occur.
Slovenian: Tako kot pri vseh cepivih se lahko pojavijo redke občasne alergijske reakcije.
English: It is sometimes associated with pain and very rarely with mild depression.
Slovenian: Včasih jih spremljata bolečina in zelo redko blaga depresija.
English: The first is given from six month of age and the second is given three to five weeks later.
Slovenian: Prva injekcija se da od šestega meseca starosti naprej, druga pa tri do pet tednov pozneje.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Equip WNV on 21 November 2008.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Equip WNV, veljavno po vsej Evropski uniji, odobrila dne 21. novembra 2008.
English: In the future, if the animals are exposed to West Nile virus the immune system will be able to respond more quickly.
Slovenian: Če bodo živali v prihodnosti izpostavljene virusu West Nile, se bo njihov imunski sistem nanj hitreje odzval.
English: It is available as an emulsion for injection.
Slovenian: Na voljo je v obliki emulzije za injiciranje.
English: The vaccine is initially given as two injections into the muscles in the neck.
Slovenian: Cepivo se najprej dvakrat injicira v mišice na predelu vratu.
English: The vaccine also contains an ‘adjuvant' to enhance the immune response.
Slovenian: Cepivo vsebuje tudi „adjuvans“ za spodbuditev imunskega odziva.
English: A number of field trials were also conducted involving vaccinated and non-vaccinated horses.
Slovenian: Opravili so tudi številne študije na terenu, v katere so bili vključeni cepljeni in necepljeni konji.
English: The laboratory studies showed that horses developed protection three weeks after the primary vaccination course.
Slovenian: Laboratorijske študije so pokazale, da so konji razvili zaščito tri tedne po osnovnem cepljenju.
English: West Nile virus strain VM-2
Slovenian: sev VM-2 virusa West Nile
English: Other information about Equip WNV:
Slovenian: Druge informacije o zdravilu Equip WNV:
English: Equip WNV is a vaccine that contains inactivated (killed) West Nile virus.
Slovenian: Zdravilo Equip WNV je cepivo, ki vsebuje inaktivirani (uničeni) virus West Nile.
English: West Nile virus is an infection that is transmitted by mosquitoes and can cause severe disease and fatal brain infections in infected horses.
Slovenian: Virus West Nile je okužba, ki jo prenašajo komarji in lahko pri okuženih konjih povzroči hudo obolenje ter smrtne okužbe možganov.
English: The withdrawal period is the time allowed after administration of the medicine and before the animal can be slaughtered and the meat used for human consumption or milk used for human consumption.
Slovenian: Karenca je časovno obdobje, ki mora preteči po uporabi zdravila, preden se lahko žival zakolje ter meso uporabi za prehrano ljudi ali mleko uporabi za prehrano ljudi.